Comparative Pharmacology
Head-to-head clinical analysis: CHLOROTHIAZIDE versus HYDROMOX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHLOROTHIAZIDE versus HYDROMOX.
CHLOROTHIAZIDE vs HYDROMOX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Chlorothiazide inhibits the Na+-Cl- symporter in the distal convoluted tubule, reducing sodium and chloride reabsorption and promoting diuresis. It also causes vasodilation by reducing peripheral vascular resistance.
Inhibits the sodium-chloride symporter (NCC) in the distal convoluted tubule of the kidney, reducing sodium and chloride reabsorption and increasing water excretion.
500 mg to 1000 mg orally or intravenously once or twice daily.
50-100 mg orally once daily; may increase to 200 mg/day for severe edema.
None Documented
None Documented
Terminal half-life: 45–120 minutes (prolonged in renal impairment); clinical context: short duration requires frequent dosing
Clinical Note
moderateHydrochlorothiazide + Digoxin
"The risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Digoxin."
Clinical Note
moderateChlorothiazide + Digoxin
"The risk or severity of adverse effects can be increased when Chlorothiazide is combined with Digoxin."
Clinical Note
moderateHydrochlorothiazide + Digitoxin
"The risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Digitoxin."
Clinical Note
moderateTerminal elimination half-life: 6-9 hours; prolonged to 24-36 hours in renal impairment (CrCl <30 mL/min)
Renal: ~95% (tubular secretion); Fecal: <5%
Renal: 70% unchanged via tubular secretion; biliary/fecal: <10%
Category C
Category C
Thiazide Diuretic
Thiazide Diuretic
Chlorothiazide + Digitoxin
"The risk or severity of adverse effects can be increased when Chlorothiazide is combined with Digitoxin."